Sensus Healthcare, Inc. — fact timeline

Sensus Healthcare, Inc. entered into Loan Agreement with City National Bank of Florida valued at $15,000,000 (effective 2026-06-02).

“On June 2, 2026, Sensus Healthcare, Inc. (the "Company") entered into a Loan Agreement (the "Loan Agreement") with City National Bank of Florida ("CNB") pursuant to which CNB has made available to the Company a revolving credit facility providing for maximum borrowings of $15,000,000”

Sensus Healthcare, Inc. shareholders approved Auditor Appointment Ratification at the 2026-05-29 meeting.

“3. Auditor Appointment Ratification . Stockholders ratified the appointment of Carr, Riggs & Ingram, LLC as the Company’s independent registered public accountant for the fiscal year ended December 31, 2026. The tabulation of votes cast was as follows: For Against Abstention 10,738,792 148,466 432,715”

Sensus Healthcare, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.

“2. Advisory Vote on Executive Compensation . Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers for 2025. The tabulation of votes cast was as follows: For Against Abstention Broker Non-Votes 4,740,572 856,128 722,554 5,000,719”

Sensus Healthcare, Inc. shareholders approved Election of Directors at the 2026-05-29 meeting.

“1. Election of Directors . Eric Sachetta and Michael J. Sardano were elected as Class II directors for a three-year term to expire in 2029. Each nominee was an incumbent director, and no other person was nominated. The tabulation of votes cast was as follows: For Against Abstention Broker Non-Votes Eric Sachetta 5,532,247 516,567 270,440 5,000,719 Michael J. Sardano 4,702,852 1,346,063 270,339 5,000,719”

Sensus Healthcare, Inc. reported the three months ended March 31, 2026 results: revenue $3.4 million.

“and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026. Highlights included: ● Revenue of $3.4 million compared to $8.3 million for the three months ended March 31, 2025. o Excluding sales to the Company’s historically largest customer, revenue increased from $2.7 million in the”

Sensus Healthcare, Inc. engaged Carr, Riggs & Ingram, LLC as its auditor.

“(the “Company”) was notified that Carr, Riggs & Ingram, LLC (“CRI”) acquired, effective as of January 1, 2026, certain assets related to the capital markets practice of Berkowitz Pollack Brant Advisors + CPAs, LLP (“BPB”). On January 13, 2026, the Audit Committee of the Company’s Board of Directors simultaneously dismissed BPB as the Company’s independent registered public accounting firm and approved the appointment of CRI as the Company’s independent registered public accounting firm.”

Sensus Healthcare, Inc. dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as its auditor.

“cquired, effective as of January 1, 2026, certain assets related to the capital markets practice of Berkowitz Pollack Brant Advisors + CPAs, LLP (“BPB”). On January 13, 2026, the Audit Committee of the Company’s Board of Directors simultaneously dismissed BPB as the Company’s independent registered public accounting firm and approved the appointment of CRI as the Company’s independent”

John Heinrich resigned as Director at Sensus Healthcare, Inc..

“Dr. Heinrich’s decision to resign”

Sensus Healthcare, Inc. reported the three months ended March 31, 2024 results: revenue $10.7 million, net income $2.3 million, or $0.14 per diluted share, EPS $0.14 per diluted share.

“Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold · Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter”

Sensus Healthcare, Inc. reported the quarter and year ended December 31, 2023 results: revenue $12.6 million, net income $4.2 million, EPS $0.26 per diluted share.

“PRESS RELEASE, DATED FEBRUARY 8, 2024 Exhibit 99.1 Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results ● Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions ● Introduces recurring revenue model for the SRT-100 VisionTM (IG-SRT) to address”

Samuel O'Rear departed as Director at Sensus Healthcare, Inc..

“On January 30, 2024, Sensus Healthcare, Inc. (the “Company”) was advised by Samuel O’Rear, a director of the Company, of his intention not to stand for reelection to the Company’s Board of Directors (the “Board”) at the Company’s 2024 annual meeting of stockholders (the “Annual Meeting”).”

Michael Sardano was appointed as Director at Sensus Healthcare, Inc..

“appointed Michael Sardano (“Mr. Sardano”) as a director, effective February 1, 2024.”

Sensus Healthcare, Inc. reported the third quarter of 2023 results: revenue $3.9 million, net income Net loss was $1.5 million, EPS $(0.09) per share.

“Sensus Healthcare Reports Third Quarter 2023 Financial Results Revenues of $3.9 million reflect seasonality and macroeconomic conditions”

Sensus Healthcare, Inc. terminated a credit facility with Silicon Valley Bridge Bank, N.A. (effective 2023-09-11).

“the Company voluntarily terminated the revolving credit facility between the Company and Silicon Valley Bridge Bank, N.A. that provided for maximum borrowings equal to the lesser of (a) the $15 million commitment amount or (b) the borrowing base plus a $7.5 million non-formula sublimit.”

Sensus Healthcare, Inc. entered into Credit Agreement with Comerica Bank valued at up to $10,000,000 (effective 2023-09-11).

“On September 11, 2023, Sensus Healthcare, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with Comerica Bank (“Comerica”) pursuant to which Comerica has made a revolving credit facility (the “Credit Facility”) available to the Company, evidenced by a Master Revolving Note, dated September 11, 2023 (the “Note”), made by the Company in favor of Comerica.”

Sensus Healthcare, Inc. reported the three and six months ended June 30, 2023 results: revenue $4.5 million, net income $0.4 million, or $0.02 per share (net loss), EPS $0.02 per share. Guidance reaffirmed.

“financial results for the three and six months ended June 30, 2023. Highlights from the second quarter of 2023 and recent weeks include the following: ● Achieved revenues of $4.5 million, an increase of 33% from $3.4 million for the first quarter of 2023 and a decrease from $12.1 million in the prior-year quarter reflecting lower SRT unit sales ● Shipped 13 SRT”

Sensus Healthcare, Inc. shareholders approved Auditor Appointment Ratification at the 2023-06-02 meeting.

“Stockholders ratified the appointment of Marcum LLP as the Company’s independent registered public accountant for the fiscal year ended December 31, 2023.”

Sensus Healthcare, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-06-02 meeting.

“Stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers for 2022.”

Sensus Healthcare, Inc. shareholders rejected Vote on Amendment of the Company's Amended and Restated Certificate of Incorporation at the 2023-06-02 meeting.

“otes cast was as follows: For Against Abstention Broker Non-Votes William McCall 7,105,077 1,699,808 46,822 2,606,110 Megan Cornish 8,572,198 231,967 47,542 2,606,110 2. Vote on Amendment of the Company’s”

Sensus Healthcare, Inc. shareholders approved Vote on Amendment of the Company's 2017 Incentive Plan at the 2023-06-02 meeting.

“Stockholders approved the amendment of the Company’s 2017 Incentive Plan to increase the number of shares that may be issued under such Plan.”

Sensus Healthcare, Inc. shareholders approved Election of Directors at the 2023-06-02 meeting.

“William McCall and Megan Cornish were each elected as a Class II director for a three-year term to expire in 2026 or until his or her successor is elected and qualified.”

Sensus Healthcare, Inc. reported the three months ended March 31, 2023 results: revenue $3.4 million, net income Net loss was $1.9 million, or $0.12 per share.

“from the first quarter of 2023 and recent weeks include the following (all comparisons are with the first quarter of 2022, unless otherwise indicated): ● Revenues were $3.4 million, compared with $10.3 million, reflecting lower SRT unit sales ● Shipped 10 systems including three SRT systems to Asia and six domestic SRT systems, compared with 33 ● Net loss”

Sensus Healthcare, Inc. reported financial results for the three and 12 months ended December 31, 2022.

“On February 9, 2023, Sensus Healthcare, Inc. announced via press release its financial results for the quarter and year ended December 31, 2022. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.”

Sensus Healthcare, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue exceed $13 million.

“PRESS RELEASE, DATED JANUARY 5, 2023. Exhibit 99.1 Sensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60% BOCA RATON, Fla, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS ), a medical device”

Magdalena Martinez was elected as Chief Operating Officer at Sensus Healthcare, Inc..

“On January 3, 2023, Magdalena Martinez was elected Chief Operating Officer of Sensus, replacing Nicolas Soro.”

Nicolas Soro departed as Chief Operating Officer at Sensus Healthcare, Inc..

“On January 3, 2023, Magdalena Martinez was elected Chief Operating Officer of Sensus, replacing Nicolas Soro.”

Sensus Healthcare, Inc. reported third quarter of 2022 results: revenue $9.0 million, net income $1.8 million, EPS $0.11 per diluted share.

“PRESS RELEASE, DATED NOVEMBER 3, 2022 Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2022 Financial Results Profitability continues with revenues up 64% to $9.0 million, diluted EPS of $0.11 compares with $0.01 a year ago Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (November 3, 2022) – Sensus Healthcare, Inc. (Nasdaq:”

Stephen Cohen resigned as Executive Vice President, Strategic Initiatives and Dermatology at Sensus Healthcare, Inc..

“Effective January 28, 2022, Stephen Cohen, Executive Vice President, Strategic Initiatives and Dermatology, of the Company, resigned.”

Joseph C. Sardano resigned as President at Sensus Healthcare, Inc..

“In connection with the election of Michael Sardano, Joseph C. Sardano, Chairman, President, and Chief Executive Officer of Sensus Healthcare, Inc. (the “Company”), resigned as President, effective January 27, 2022.”

Michael J. Sardano was elected as President at Sensus Healthcare, Inc..

“On January 27, 2022, Michael J. Sardano was elected President of the Company, to serve until the next annual meeting of the Company’s Board of Directors, subject to his earlier resignation, removal, or death.”